Oncotarget

Research Papers:

Additive analgesic effect of dexmedetomidine and dezocine administered intrathecally in a mouse pain model

Ya-Qin Huang, Shao-Hui Guo, Renyu Liu, Sheng-Mei Zhu, Jian-Liang Sun and Yong-Xing Yao _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:24391-24397. https://doi.org/10.18632/oncotarget.25304

Metrics: PDF 994 views  |   HTML 1120 views  |   ?  


Abstract

Ya-Qin Huang1,2,3, Shao-Hui Guo1, Renyu Liu4, Sheng-Mei Zhu1, Jian-Liang Sun2 and Yong-Xing Yao1,3

1Department of Anesthesia, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P. R. China

2Department of Anesthesia, Hangzhou Hospital Affiliated With Nanjing Medical University, Hangzhou First People’s Hospital, Hangzhou, P. R. China

3Department of Anesthesia, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, P. R. China

4Department of Anesthesiology and Critical Care, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA

Correspondence to:

Yong-Xing Yao, email: yaoyongxing7323@163.com, yaoyongxing@zju.edu.cn

Jian-Liang Sun, email: jxmzsjl@163.com

Keywords: dexmedetomidine; dezocine; analgesia; acute nociception

Received: August 30, 2017     Accepted: April 07, 2018     Published: May 11, 2018

ABSTRACT

Background: It is known that dexmedetomidine can reduce opioid requirements and that there is a synergistic effect when dexmedetomidine and morphine (a full mu opioid receptor agonist) are administered together. However, it was unclear whether a synergistic or additive effect would be observed when dexmedetomidine was co-administered with a partial mu opioid receptor agonist. The present study was designed to elucidate such effects by intrathecally co-administering dexmedetomidine and dezocine, a partial mu receptor agonist, in a mouse pain model.

Methods: C57 mice (N = 165) were randomly divided into 19 groups. The tail flick test was adopted to measure the antinociceptive effects of the tested agents. The mice were divided into saline and drug groups to investigate the dose-dependent analgesic effects. Each drug was administered at fixed doses alone and in combination with one of three doses of a second drug.

Results: Dezocine (0.3125 - 1.25 μg) and dexmedetomidine (0.04 - 1 μg) both enhanced the tail withdrawal latency in dose-dependent fashions. Dexmedetomidine (0.04 - 1 μg) enhanced the analgesic effect of dezocine. Dezocine (0.3125 - 1.25 μg) enhanced the analgesic effect of dexmedetomidine. Compared with the individual drug effects, the combined effects of dezocine (0.625 μg) and dexmedetomidine (0.04 μg) were more potent 15 - 60 min after injection, but they remained similar to the sum of the effects of the two individual drugs.

Conclusions: Dexmedetomidine and dezocine produce an additive analgesic effect on acute nociception when administered simultaneously.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25304